Wells Fargo cuts CRISPR Therapeutics stock price target on earnings
Wells Fargo cuts CRISPR Therapeutics stock price target on earnings Investing.com
Covered in this story
What has happened since
- Wells Fargo is down 1.6% since this was published, 10 days ago.
- Crispr Therapeutics AG is down 18.4% since this was published, 10 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Wells Fargo’s $70 target on $CRSP is on the record and being tracked to Nov 2027 (12-month default), scored on the close that day.
Wells Fargo’s track record →Analyst targets on Wells Fargo
- Citi: at $80.7 · target $88 by Oct 2027 · Neutral via MarketBeat
- RBC Capital Markets: at $79.9 · target $92 by Oct 2027 · Outperform via TradingView
- TD Cowen: at $81.6 · target $95 by Oct 2027 via GuruFocus
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $WFC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Wells Fargo →Dalsna Finance is currently tracking 51 stories mentioning Wells Fargo, the earliest published 28 Apr 2017.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.